Source: Benzinga

Karyopharm: MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, Sept. 23, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Karyopharm Therapeutics Inc. ("Karyopharm" or "the Company") (NASDAQ: KPTI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's shares between March 2, 2017 and February 22, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before September 23, 2019. If you are a shareholder who suffered a loss, click here to participate.We ...Full story available on

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Based on data from Karyopharm's latest SEC filings

Annual Revenue

Based on data from Karyopharm's latest SEC filings


Michael G. Kauffman's photo - Co-Founder & CEO of Karyopharm

Co-Founder & CEO

Michael G. Kauffman

CEO Approval Rating


Karyopharm researches and develops therapeutics for the treatment of cancer.

Karyopharm's headquarters is in Newton, Mass...
Read more